Suzhou Qiaoji Biotechnology Co., Ltd.

Dose escalation study: Primary purpose: To evaluate the safety and tolerability of BGC515 capsules in patients with malignant mesothelioma (MM), epithelioid hemangioendothelioma (EHE) or other advanced solid tumors. To explore dose-limiting toxicity and maximum tolerated dose. Secondary purpose: To evaluate the pharmacokinetics of BGC515 capsules in patients with MM, EHE or other advanced solid tumors. To preliminarily evaluate the efficacy of BGC515 capsules in patients with MM, EHE or other advanced solid tumors. Exploratory purpose: Exploratory biomarker study. Dose expansion study: Primary purpose: To further evaluate the safety and tolerability of BGC515 capsules in patients with MM, EHE, glioblastoma or other advanced solid tumors with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation, and determine the recommended dose for Phase II. To evaluate the preliminary efficacy of BGC515 capsules in patients with MM, EHE, glioblastoma or other advanced solid tumors with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation. Secondary objective: To evaluate the PK of BGC515 capsules in patients with MM, EHE, glioblastoma or other advanced solid tumors with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation. Exploratory objective: Exploratory biomarker study.